


ChemComm

Chemical Communications

www.rsc.org/chemcomm



ISSN 1359-7345



COMMUNICATION

Christopher J. Schofield *et al.*

Fluoromethylated derivatives of carnitine biosynthesis
intermediates – synthesis and applications

Cite this: *Chem. Commun.*, 2014, 50, 1175

Received 2nd October 2013,
Accepted 20th November 2013


DOI: 10.1039/c3cc47581f

www.rsc.org/chemcomm

A convenient method for the synthesis of fluoromethylated carnitine biosynthesis intermediates, i.e. fluorinated derivatives of γ -butyrobetaine and trimethyllysine, is described. The fluoromethylated probes were useful in both *in vitro* and cell based assays employing ^{19}F NMR and LC-MS analyses.

Carnitine, an essential metabolite in humans and other eukaryotes, is vital for the transport of long chain fatty acids into mitochondria.¹ In animals carnitine is biosynthesised from trimethyllysine (TML) in four enzyme-catalysed steps.²⁻⁴ The first and last steps in the pathway are catalysed by trimethyllysine hydroxylase (TMLH) and γ -butyrobetaine hydroxylase (BBOX), both of which belong to the 2-oxoglutarate (2OG) dependent oxygenase superfamily. TMLH and BBOX catalyse the hydroxylation of N^c -trimethyllysine (TML, (1)) and γ -butyrobetaine (GBB, (3)) respectively (Scheme 1A).^{5,6} The inhibition of human carnitine biosynthesis reduces fatty acid metabolism and has been targeted for the treatment of cardiovascular diseases.^{7,8} With respect to efforts aimed at understanding biological roles of 2OG dependent oxygenases in carnitine metabolism,^{9,10} we are interested in developing reagents that enable assays for carnitine biosynthesis enzyme activities, both *in vitro*¹¹ and in more biologically representative systems. Given that the monofluoromethyl group is similar in size to the methyl group, we envisioned fluoromethylated GBB (9) and TML (11) analogues as potentially useful tool compounds for monitoring carnitine biosynthesis.

Organofluorine compounds have substantial applications in chemistry and chemical biology; their applications include the modification of physicochemical and conformational properties of small molecules, and use as tracers in radiomedicine¹² or



Scheme 1 Synthesis of fluorinated analogues of carnitine biosynthesis metabolites. A – the carnitine biosynthesis pathway in mammals. B – preparation of fluoromethylating agent (7). C – synthesis of fluorinated derivative of γ -butyrobetaine (GBBNF, (9)) and trimethyllysine (TMLNF, (11)). NBS – *N*-bromosuccinimide; Tf₂O – trifluoromethanesulfonic anhydride.

labels in NMR studies.^{13,14} ^{19}F NMR is emerging as a valuable tool for studying biochemical processes *in vitro* and *in vivo*.¹⁵ The principle advantage of ^{19}F NMR is that the absence of endogenous fluorinated species in most living organisms eliminates the problem of background interference and signal overlap. However, the use of ^{19}F NMR is often limited by the availability of appropriately labeled fluorinated compounds.

Various approaches for the incorporation of fluorine into small molecules are available, but reagents for electrophilic monofluoromethylation are limited.¹⁶ Prakash *et al.* reported an air and moisture stable electrophilic fluoromethylating reagent (7) that reacts under mild conditions¹⁷ with various nucleophiles, including amines.^{17,18} The reported preparation of (7) required

^a Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford OX1 3TA, UK.

E-mail: christopher.schofield@chem.ox.ac.uk

^b Structural Genomics Consortium, University of Oxford, Old Road Campus Roosevelt Drive, Headington OX3 7DQ, UK

[†] Electronic supplementary information (ESI) available: Synthesis procedures, assay conditions, and NMR assignments. See DOI: 10.1039/c3cc47581f

[‡] Current address: Navarrabiomed-Fundacion Miguel Servet, C/Irunlarrea 3, Complejo Hospitalario de Navarra, 31008 Pamplona, Navarra, Spain.



the use of liquefied CH_2FCl , which can be inconvenient. We therefore employed a route where chloromethylphenyl sulphide (5) was converted to the corresponding fluoride by reaction with caesium fluoride¹⁹ and then directly oxidised with aqueous *N*-bromosuccinimide to yield fluoromethylsulphinyll benzene (6) – a known intermediate in the synthesis of the fluoromethylating reagent (7) (Scheme 1B). We then used (7) to efficiently prepare *N*- CH_2F modified derivatives of GBB (3) and TML (1) in 2 or 3 steps, respectively, starting from appropriately protected *N,N*-dimethylated precursors (Scheme 1C).

The fluoromethylated GBB analogue (GBBNF, (9)) was evaluated in reaction with the purified recombinant human BBOX (hBBOX) *in vitro*. GBBNF (9) was found to be a hBBOX substrate as demonstrated by ¹H NMR analyses (Fig. S1, ESI[†]) undergoing hydroxylation at the C3 position to give a fluoromethylated carnitine analogue (CARNF) (14) (Fig. 1C; for NMR assignment of the product see Fig. S2–S4, ESI[†]), in an analogous manner to hBBOX catalysed GBB hydroxylation (Fig. 1A). We have reported the synthesis of another fluorinated analogue of GBB – (3*S*)-fluoro-GBB (GBBF, (12)), C-3 hydroxylation of which leads to fluoride release concomitant with ketone (13) formation (Fig. 1B).¹¹ In NMR assays we did not observe fluoride release in reaction of GBBNF (9) with hBBOX, indicating that the fluoromethylated quaternary ammonium group is stable under the assay conditions. Comparison of the initial rates of hydroxylation of GBB (3), GBBNF (9) and GBBF (12) by hBBOX revealed that GBBNF (9) is a better substrate than GBBF (12) (Table 1, Fig. 1). The initial hydroxylation rate of GBBNF (9) is ~65% of the initial hydroxylation rate of GBB (3), while GBBF (12) is hydroxylated at ~20% of the initial rate of GBB (3). The K_M and k_{cat} values also reveal that the properties of GBBNF (9) as a substrate are closer to those of GBB (3) than GBBF (12) (Table 1). Some 2OG dependent oxygenases catalyse turnover of 2OG independent of




Fig. 1 Reactions catalysed by BBOX. GBBNF is a BBOX substrate and undergoes hydroxylation in a position analogous to GBB hydroxylation. Time dependent product formation reveals that GBBNF is a better substrate than GBBF.

Table 1 Kinetic properties of fluorinated GBB analogues

		GBB (3)	GBBF (12)	GBBNF (9)
Rate [$\mu\text{M s}^{-1}$]	Hydroxylation	0.123	0.027	0.083
	Succinate formation	0.162	0.063	0.097
Ratio of succinate formation to hydroxylation		1.1	2	1.3
Kinetic parameters	K_M [μM]	4.2	19.8	16.6
	k_{cat} [s^{-1}]	0.83	0.14	0.30
	K_i [μM]	24.5	135	—

substrate transformation (uncoupled 2OG turnover)⁵ which can manifest with a poor substrate.²⁰ We examined levels of uncoupled turnover when GBB (3) and its fluorinated analogues were used, by comparing rates of succinate formation to that of hydroxylation. The results showed GBBNF (9) to be similar to GBB (3) (ratio of succinate formation to hydroxylation 1.1 for GBB vs. 1.3 for GBBNF), while in the case of GBBF (12), the ratio was ~2:1 (Table 1 and Fig. S5, ESI[†]). Note that, as for GBB (3), GBBF (12) displays substantial substrate inhibition (apparently K_i values in micromolar range – see Table 1). Interestingly, the extent of substrate inhibition by GBBNF (9) was much less than for GBB (3) or GBBF (12) (Fig. S6, ESI[†]). The mechanism of substrate inhibition of hBBOX is unknown, but is of interest as it may be involved in regulating carnitine biosynthesis in cells.

hBBOX catalysed GBBNF (9) hydroxylation can be followed by ¹⁹F NMR, because the fluorine shift of the product is distinctively different from a shift of the substrate (Fig. 2A). In these compounds the ¹⁹F resonance appears with a 1:1:1 triplet fine structure, not as a singlet. This structure arises from coupling of the fluorine to the adjacent quadrupolar ¹⁴N nucleus ($I = 1$, 99.6% abundance) and is




Fig. 2 Applications of GBBNF (9). A – conversion of GBBNF to CARNF by psBBOX can be followed by ¹⁹F NMR. B – ¹⁹F NMR based assay enables determination of dose–response curves for potential inhibitors, exemplified with the hBBOX inhibitor Mildronate. C – SDS-PAGE gel shows lysate samples from cells harvested at various times after IPTG induction (lanes 4–8). Molecular weight marker (lane 1), BBOX sample (lane 2) and uninduced cells harvested after 24 h (lane 3) are shown. BBOX activity in cell lysates can be quantified by ¹⁹F NMR.






Fig. 3 Levels of CAR (4), GBB (3) and GBBNF (9) in HEK 293T cells: A – control, B – treated with TML (1), C – treated with TMLNF (11). Error bars represent standard deviation of $n = 3$ samples.

apparent because the highly symmetrical tetrahedral environment of the ^{14}N centre suppresses rapid quadrupolar relaxation that, in less symmetrical environments, leads to loss of coupling fine structure. ^{19}F NMR can also be employed for IC_{50} measurements (Fig. 2B). We investigated hBBOX inhibition by Mildronate,⁷ which is an inhibitor and a competitive substrate for hBBOX.^{9,10} The obtained IC_{50} value (82 μM) is similar to that obtained by ^1H NMR (34 μM) and fluoride release (65 μM) assays.¹¹ The differences likely reflect the different assay conditions used. Thus, ^{19}F NMR assay employing GBBNF (9) as a substrate is useful for *in vitro* activity studies. An advantage of the GBBNF (9) based system is its ability to monitor specific hBBOX turnover without the interference of any other non-fluorinated components, making it suitable for biologically relevant assay conditions.

To test the turnover of fluorinated analogues in cells we used *E. coli* BL21 cells producing a prokaryotic BBOX homologue from *Pseudomonas* sp. AK1 (psBBOX). We observed that GBBNF (9) is converted to CARNF (14) in crude cell lysates, provided that 2OG was added to the reaction mixture, and that the turnover level is dependent on 2OG concentration (Fig. S7, ESI†). The extent of GBBNF (9) turnover is dependent on the amount of psBBOX present in the extracts (Fig. 2C and Fig. S8, ESI†). Thus, ^{19}F NMR can be used to estimate psBBOX activities in cell lysates.

In addition to the use as a label for ^{19}F NMR studies, fluorine is a convenient marker for small molecules in MS based studies. We therefore investigated the metabolism of TMLNF (11) in human embryonic kidney cells (HEK 293T cells) using LC-MS. HEK 293T cells were grown either with or without TML (1) or TMLNF (11) added to the growth media. Cells were harvested, lysed and analysed for the carnitine related metabolites (Fig. 3), using appropriate standards (Fig. S10, ESI†). In none of the samples could TML (1) or TMLNF (11) be detected. In the sample treated with TML (1), elevated levels of GBB (3) were observed, indicating that TML (1) penetrates cell membranes and is converted to GBB (3). Cells treated with TMLNF (11) contained lower amounts of GBB (3) than controls and substantial levels of GBBNF (9), which can only be formed from TMLNF (11), demonstrating that TMLNF (11) is carried through the first enzyme catalysed step of carnitine biosynthesis. All of the samples contained similar levels of carnitine (within error), but no CARNF (14) was observed in the TMLNF (11)

treated sample; this result may reflect the differences in affinities of GBB (3) and GBBNF (11) to hBBOX, as observed by *in vitro* kinetic data (Table 1).

In conclusion we have described an efficient procedure for the synthesis of the electrophilic monofluoromethylation reagent¹⁷ (7) that enables convenient preparation of fluoromethylated quaternary ammonium derivatives, *e.g.* trimethyllysine and carnitine related compounds. The utility of these compounds in enzymatic assays was demonstrated employing ^{19}F NMR with recombinant hBBOX and crude cell lysates. LC-MS studies enabled tracking of fluorinated intermediates in human cells. Quaternary ammonium derivatives have widespread pharmaceutical and industrial applications *e.g.* as antimicrobial agents²¹ or phase transfer catalysts in organic chemistry.²² They are also a ubiquitous class of metabolites, present in all living organisms.²³ In humans and animals *N*-methylated lysine, arginine and nucleic acid compounds play crucial roles in epigenetic regulation. We hope that the development of appropriate fluorinated small molecules will enable work aimed at understanding the role of methylation in epigenetics.

We thank the Wellcome Trust, Biotechnology and Biological Sciences Research Council, European Union, Dulverton Trust (A.M.R.) and Cancer Research UK (A.T.) for financial support.

Notes and references

- 1 R. J. Wanders, P. Vreken, M. E. den Boer, F. A. Wijburg, A. H. van Gennip and L. Ijlst, *J. Inherited Metab. Dis.*, 1999, **22**, 442–487.
- 2 K. Strijbis, F. M. Vaz and B. Distel, *IUBMB Life*, 2010, **62**, 357–362.
- 3 C. Hoppel, *Am. J. Kidney Dis.*, 2003, **41**, S4–S12.
- 4 C. J. Rebouche and H. Seim, *Annu. Rev. Nutr.*, 1998, **18**, 39–61.
- 5 R. P. Hausinger, *Crit. Rev. Biochem. Mol. Biol.*, 2004, **39**, 21–68.
- 6 C. Loenarz and C. J. Schofield, *Nat. Chem. Biol.*, 2008, **4**, 152–156.
- 7 M. Dambrova, E. Liepinsh and I. Kalvinsh, *Trends Cardiovasc. Med.*, 2002, **12**, 275–279.
- 8 Y. Hayashi, T. Kirmoto, N. Asaka, M. Nakano, K. Tajima, H. Miyake and N. Matsuura, *Eur. J. Pharmacol.*, 2000, **395**, 217–224.
- 9 I. K. H. Leung, T. J. Krojer, G. T. Kochan, L. Henry, F. Von Delft, T. D. W. Claridge, U. Oppermann, M. A. McDonough and C. J. Schofield, *Chem. Biol.*, 2010, **17**, 1316–1324.
- 10 L. Henry, I. K. H. Leung, T. D. W. Claridge and C. J. Schofield, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 4975–4978.
- 11 A. M. Rydzik, I. K. H. Leung, G. T. Kochan, A. Thalhammer, U. Oppermann, T. D. W. Claridge and C. J. Schofield, *ChemBioChem*, 2012, **13**, 1559–1563.
- 12 S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, *Chem. Soc. Rev.*, 2008, **37**, 320–330.
- 13 A. Vulpetti and C. Dalvit, *Drug Discovery Today*, 2012, **17**, 890–897.
- 14 C. Dalvit, *Prog. Nucl. Magn. Reson. Spectrosc.*, 2007, **51**, 243–271.
- 15 H. Chen, S. Viel, F. Ziarelli and L. Peng, *Chem. Soc. Rev.*, 2013, **42**, 7971–7982.
- 16 J. Hu, W. Zhang and F. Wang, *Chem. Commun.*, 2009, 7465–7478.
- 17 G. K. S. Prakash, I. Ledneczki, S. Chacko and G. A. Olah, *Org. Lett.*, 2008, **10**, 557–560.
- 18 G. K. S. Prakash and S. Chacko, *Curr. Opin. Drug Discovery Dev.*, 2008, **11**, 793–802.
- 19 D. P. Matthews, R. A. Persichetti and J. R. McCarthy, *Org. Prep. Proced. Int.*, 1994, **26**, 605–608.
- 20 E. Flashman, S. L. Davies, K. K. Yeoh and C. J. Schofield, *Biochem. J.*, 2010, **427**, 135–142.
- 21 M. Tischer, G. Pradel, K. Ohlsen and U. Holzgrabe, *ChemMedChem*, 2012, **7**, 22–31.
- 22 T. Ooi and K. Maruoka, *Angew. Chem., Int. Ed.*, 2007, **46**, 4222–4266.
- 23 U. Anthoni, C. Christoffersen, L. Hougaard and P. H. Nielsen, *Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol.*, 1991, **99**, 1–18.

